Wednesday, October 23, 2019
News
NEWS HOME
»
PRESS RELEASES

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1
  SocialTwist Tell-a-Friend  
   


Date: 21-05-2019 12:28PM
Source: Boehringer Ingelheim
Category: General, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Ingelheim, Germany

Business Wire India

  • Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine(NEJM) and presented at the American Thoracic Society Conference in Dallas, USA
  • Interstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3
  • FDA grants priority review to application for regulatory approval for nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD)


Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVCa) in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD). Results show thatnintedanib slows the loss of pulmonary function in patients with SSc-ILD compared to placebo. Patients taking nintedanib showed a 44% reduction in the rate of decline of their lung function, measured in FVC assessed over 52 weeks1. These new data were today published in the New England Journal of Medicine (NEJM) and presented to the medical community at the American Thoracic Society (ATS) International Conference, in Dallas, USA.

SENSCIS® is the largest randomised controlled trial to be conducted in patients with SSc-ILD, a disease for which there are currently no approved treatments.1,3,4 Results also showed that nintedanib had a safety and tolerability profile similar to that observed in patients with idiopathic pulmonary fibrosis (IPF)1, with the most common adverse event being diarrhoea. Nintedanib is already approved in more than 70 countries for the treatment of IPF. These trial results formed the basis of the application for regulatory approval of nintedanib in SSc-ILD that was filed with the FDA and EMA by Boehringer Ingelheim in the first quarter of 2019. The FDA recently granted priority review to the supplemental application for nintedanib in SSc-ILD. The regulatory submissions are part of the company’s ongoing commitment to improving the lives of people living with pulmonary fibrosis, in particular those affected by rare diseases with a high level of unmet need.

Systemic sclerosis, also known as scleroderma, is a rare incurable autoimmune disease affecting connective tissue.3,4,5 It can cause scarring (fibrosis) of the skin as well as major organs such as the heart, lungs, digestive tract and kidneys and can have life-threatening complications.2,3 Approximately 25 percent of patients develop significant pulmonary involvement within three years of diagnosis.6 When SSc affects the lungs it can cause interstitial lung disease (ILD), known as SSc-ILD.2,3 It is a key driver of mortality among people with SSc, accounting for approximately one third of deaths.7,8

SENSCIS®, a Phase III double-blind, randomised, placebo-controlled trial, involved 576 patients across more than 32 countries. The primary endpoint was the annual rate of decline in FVC in mL over 52 weeks.1 At the end of the 52-week trial, patients receiving nintedanib had an adjusted annual rate of decline in FVC (mL/year) of -52.4 with nintedanib, versus -93.3 with placebo (absolute difference 41.0mL/year [95% CI 2.9, 79.0]; p=0.04). This corresponds to a relative difference of 44% reduction in lung function decline1,similar to the results from the Phase III INPULSIS® trials in IPF.12 FVC is an established measurement of lung function. As ILD progresses, lung function gradually and irreversibly deteriorates.9

“The SENSCIS results provide positive news for people living with SSc-ILD and their physicians because currently there are no approved treatments” explained Professor Oliver Distler, Professor of Rheumatology, University Hospital Zurich and lead investigator of the trial. “A 44% reduction in lung function decline indicates a significant slowdown in disease progression. Nintedanib could make a considerable difference to the lives of people with this rare and often life-threatening disease.”

“We are pleased to be able to share the positive results of the pivotal SENSCIS trial that are very consistent with the database from IPF and formed the basis of the recent submissions Boehringer Ingelheim made to the FDA and EMA for regulatory approval of nintedanib in February and March 2019”, said Dr. Susanne Stowasser, Associate Head of Medicine, Respiratory at Boehringer Ingelheim. “Fibrotic lung diseases including SSc-ILD continue to have a devastating impact on people’s lives and our focus remains on making treatments available to improve the lives of patients in areas of high unmet need.”

~ENDS~

Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/nintedanib-slows-pulmonary-function-loss-in-people-with-ssc-ild



CONTACTS :

Boehringer Ingelheim
Corporate Communications
Media + PR
Alexander Kurz
55216 Ingelheim/Germany
Tel.: +49 (6132) 77-184531
Mobile: +49 (151) 68948378
Email: press@boehringer-ingelheim.com

More Press Releases

The 4th Edition of UNESCO-Merck Africa Research Summit– MARS 2019 to Be Conducted by Merck Foundation in Accra, Ghana

National Committee on Textiles & Clothing (NCTC) Proposes Measures to Boost the Textile and Clothing Industry

Wipro Selected as Dow Jones Sustainability World Index (DJSI) Member for the Tenth Consecutive Year

Enjoy a Fresh and Clean Diwali Season With HiCare's Services

Beverage Carton Industry Joins Forces Globally to Drive Action on Sustainability

AROMA BIT Secures 350mn JPY in Series A Funding from Japan Tobacco and East Ventures

Alibaba Kicks Off 2019 11.11 Global Shopping Festival

Delhi’s Vivaan Gupta Becomes the Youngest Indian to Travel All Continents of the World

Growing Sustainability Concerns Will Shape the Indian Soft Drinks Industry

Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFa Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease

ADX Group Announces IPO Progress, New Cyber Security Offerings

Delta Launches Its Latest Power Quality Solutions and 4K Laser DLP® Video Wall for Railway Transportation at IREE 2019

Kartik Mohindra Now a Part of Keepers of the Quaich, a Global Celebration of Scotch Whisky

Topcoder On-Demand Digital Talent Platform Includes New Data Science, AI Features to Advance Enterprise Analytics

Marconi Society's Celestini Program Recognizes Indian Students Tackling Women's Safety & Air Pollution

Market Leading Manufacturing Companies in India Recognized for Their Global Competitiveness

Winners of “Merck More Than a Mother” Fashion Awards - Zambia Announced by Merck Foundation With the Aim to Break the Stigma Around Infertile Women

Raysut Cement Subsidiary, Pioneer Cement, to Develop USD200 Million Georgia Cement Project

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Court dismisses complaint against Gambhi...
Haryana had 68.31 per cent polling...
Ashok Malik appointed Policy Advisor in ...
Ex-BJP MLA claims daughter victim of lov...
US welcomes Indian govt action to stabil...
Conrad Sangma meets Modi, seeks central ...
More...    
 
 Top Stories
14 gunmen killed in encounter in Bu... 
Baloch women, children hold protest... 
UN to focus on prevention of resume... 
British PM's Brexit timetable rejec... 
British PM's Brexit timetable rejec... 
Kurdish forces leave Syria border a... 
Delhi: 22-year-old arrested for kil... 
2 dead after grenade explodes in Uk...